Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 12/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8119431 | 0.85 | HTR5A (0.34) | HTR5AIDO1MEN1GAAMAPT | |
| SCHEMBL14030433 | 0.77 | IDO1 (0.46) | IDO1MEN1GAAMAPTKMT2A | |
| SCHEMBL1879473 | 0.74 | HTR5A (0.43) | HTR5AIDO1ALDH1A1EGFR | |
| SCHEMBL15867657 | 0.70 | HTR5A (0.38) | HTR5AIDO1GAAMAPTEGFR | |
| SCHEMBL29167137 | 0.69 | HTR5A (0.39) | HTR5AIDO1ALDH1A1EGFR | |
| SCHEMBL15723614 | 0.69 | HTR5A (0.36) | HTR5AIDO1MEN1MAPTKMT2A | |
| SCHEMBL25758588 | 0.69 | HTR5A (0.36) | HTR5AIDO1MEN1MAPTKMT2A | |
| SCHEMBL15867658 | 0.69 | TSHR (0.36) | HTR5AALDH1A1 | |
| SCHEMBL15867655 | 0.67 | HTR5A (0.32) | HTR5AALDH1A1 | |
| SCHEMBL12900944 | 0.67 | HTR5A (0.34) | HTR5AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188080-B2 | VHR protein tyrosine phosphatase inhibitors, compositions and methods of use | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090105254-A1 | VHR PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105254-A1 | VHR PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | PTPRR, PTPRS, PTPRCAP | HTR5A 2979/4885IDO1 1108/4885MEN1 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.